# The Columbia PCC for CureGN: the Cure Glomerulonephropathy network

> **NIH NIH U01** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $924,999

## Abstract

Abstract
Primary glomerular diseases, including minimal change disease (MCD), focal segmental glomerulosclerosis
(FSGS), immunoglobulin A nephropathy (IgAN), and membranous nephropathy (MN), are associated with
significant morbidity and mortality in both adults and children. The Cure Glomerulonephropathy (CureGN)
study launched in 2013 to address critical knowledge gaps in the disease pathogenesis, natural history, and
response to therapy of these heterogeneous disorders. It is a study of unprecedented size and remarkable
depth, built by a unique, collaborative, interdisciplinary community. The international consortium includes
researchers with diverse expertise, affected patients and advocacy groups, the biopharmaceutical industry,
and federal funding agencies. CureGN has successfully recruited a diverse cohort of nearly 2800 adult and
pediatric participants with MCD, FSGS, IgAN, and MN from more than 60 clinical study sites into a prospective,
longitudinal, observational cohort study. Biospecimens, clinical data, and patient-reported outcomes are
collected to enable high-quality clinical, mechanistic, and translational investigations. This foundational work is
being conducted by a well-functioning collaborative group including the Data Coordinating Center (at the
University of Michigan, Northwestern University, and Cleveland Clinic) and four Participating Clinical Centers
(managed at the University of Pennsylvania, Columbia University, University of North Carolina, and the
Pediatric Nephrology Research Consortium). CureGN will pave the way for personalized care in glomerular
disease by disentangling the heterogeneity of disorders that are etiologically diverse but currently grouped into
only four diagnoses.
In CureGN’s third study phase, we propose to maintain and enhance the CureGN Consortium infrastructure
and ancillary study program to accelerate patient-relevant glomerular disease research. We will continue our
core observational study, enrolling additional participants in a recruit-to-replace strategy to maintain an active
cohort of 2000 participants with high-quality clinical data and biomaterials. We will implement state-of-the-art
data collection tools including remote data and biospecimen collection, new biospecimen types, and use of
mobile devices for patient-facing engagement and medical record linkages. Mature scientific working groups,
committees and ancillary infrastructure will continue to support a multidisciplinary core and ancillary study
program to achieve the scientific goals of CureGN. We will continue outreach to the scientific community by
expanding CureGN’s role as an outstanding training vehicle for the next generation of glomerular disease
researchers and attracting cutting-edge, established scientists to glomerular disease through opportunity pool
grants, collaborations with patient advocacy groups and professional societies, training workshops, and
support of ancillary studies from academic and industry partners. Thr...

## Key facts

- **NIH application ID:** 10973015
- **Project number:** 2U01DK100876-12
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** Andrew Stephen Bomback
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $924,999
- **Award type:** 2
- **Project period:** 2013-09-16 → 2029-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10973015

## Citation

> US National Institutes of Health, RePORTER application 10973015, The Columbia PCC for CureGN: the Cure Glomerulonephropathy network (2U01DK100876-12). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10973015. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*